PortalPublikationenFamily with sequence similarity 13C (FAM13C) overexpression ...

Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer

Standard

Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer. / Burdelski, Christoph; Borcherding, Laura; Kluth, Martina; Hube-Magg, Claudia; Melling, Nathaniel; Simon, Ronald; Möller-Koop, Christina; Weigand, Philipp; Minner, Sarah; Haese, Alexander; Michl, Hans Uwe; Tsourlakis, Maria Christina; Jacobsen, Frank; Hinsch, Andrea; Wittmer, Corinna; Lebok, Patrick; Steurer, Stefan; Izbicki, Jakob R; Sauter, Guido; Krech, Till; Büscheck, Franziska; Clauditz, Till; Schlomm, Thorsten; Wilczak, Waldemar.

in: ONCOTARGET, Jahrgang 8, Nr. 19, 09.05.2017, S. 31494-31508.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Burdelski, C, Borcherding, L, Kluth, M, Hube-Magg, C, Melling, N, Simon, R, Möller-Koop, C, Weigand, P, Minner, S, Haese, A, Michl, HU, Tsourlakis, MC, Jacobsen, F, Hinsch, A, Wittmer, C, Lebok, P, Steurer, S, Izbicki, JR, Sauter, G, Krech, T, Büscheck, F, Clauditz, T, Schlomm, T & Wilczak, W 2017, 'Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer', ONCOTARGET, Jg. 8, Nr. 19, S. 31494-31508. https://doi.org/10.18632/oncotarget.16357

APA

Burdelski, C., Borcherding, L., Kluth, M., Hube-Magg, C., Melling, N., Simon, R., Möller-Koop, C., Weigand, P., Minner, S., Haese, A., Michl, H. U., Tsourlakis, M. C., Jacobsen, F., Hinsch, A., Wittmer, C., Lebok, P., Steurer, S., Izbicki, J. R., Sauter, G., ... Wilczak, W. (2017). Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer. ONCOTARGET, 8(19), 31494-31508. https://doi.org/10.18632/oncotarget.16357

Vancouver

Burdelski C, Borcherding L, Kluth M, Hube-Magg C, Melling N, Simon R et al. Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer. ONCOTARGET. 2017 Mai 9;8(19):31494-31508. https://doi.org/10.18632/oncotarget.16357

Bibtex

@article{59a6c8cb71dd4f2b8e250ce3fce100ca,
title = "Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer",
abstract = "FAM13C, a gene with unknown function is included in several mRNA signatures for prostate cancer aggressiveness. To understand the impact of FAM13C on prognosis and its relationship to molecularly defined subsets, we analyzed FAM13C expression by immunohistochemistry on a tissue microarray containing 12,400 prostate cancer specimens. Results were compared to phenotype, ERG status, genomic deletions of 3p, 5q, 6q and PTEN, and biochemical recurrence. FAM13C was detectable in cell nuclei of cancerous and non-neoplastic prostate cells. 67.5% of 9,633 interpretable cancers showed FAM13C expression: strong in 28.3%, moderate in 24.6% and weak in 14.6%. Strong FAM13C expression was linked to advanced pT stage, high Gleason grade, positive lymph node status, and early biochemical recurrence (p < 0.0001 each). FAM13C expression was associated with TMPRSS2:ERG fusions. It was present in 85% of ERG positive but in only 54% of ERG negative cancers (p < 0.0001), and in 91.1% of PTEN deleted but in only 69.2% of PTEN non-deleted cancers (p < 0.0001). The prognostic role of FAM13C expression was independent of classical and quantitative Gleason grade, pT stage, pN stage, surgical margin status and preoperative PSA. In conclusion, the results of our study demonstrate that expression of FAM13C is an independent prognostic marker in prostate cancer. Finding FAM13C also in non-neoplastic prostate tissues highlights the importance of properly selecting cancer-rich areas for RNA-based FAM13C expression analysis.",
keywords = "Journal Article",
author = "Christoph Burdelski and Laura Borcherding and Martina Kluth and Claudia Hube-Magg and Nathaniel Melling and Ronald Simon and Christina M{\"o}ller-Koop and Philipp Weigand and Sarah Minner and Alexander Haese and Michl, {Hans Uwe} and Tsourlakis, {Maria Christina} and Frank Jacobsen and Andrea Hinsch and Corinna Wittmer and Patrick Lebok and Stefan Steurer and Izbicki, {Jakob R} and Guido Sauter and Till Krech and Franziska B{\"u}scheck and Till Clauditz and Thorsten Schlomm and Waldemar Wilczak",
year = "2017",
month = may,
day = "9",
doi = "10.18632/oncotarget.16357",
language = "English",
volume = "8",
pages = "31494--31508",
journal = "ONCOTARGET",
issn = "1949-2553",
publisher = "IMPACT JOURNALS LLC",
number = "19",

}

RIS

TY - JOUR

T1 - Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer

AU - Burdelski, Christoph

AU - Borcherding, Laura

AU - Kluth, Martina

AU - Hube-Magg, Claudia

AU - Melling, Nathaniel

AU - Simon, Ronald

AU - Möller-Koop, Christina

AU - Weigand, Philipp

AU - Minner, Sarah

AU - Haese, Alexander

AU - Michl, Hans Uwe

AU - Tsourlakis, Maria Christina

AU - Jacobsen, Frank

AU - Hinsch, Andrea

AU - Wittmer, Corinna

AU - Lebok, Patrick

AU - Steurer, Stefan

AU - Izbicki, Jakob R

AU - Sauter, Guido

AU - Krech, Till

AU - Büscheck, Franziska

AU - Clauditz, Till

AU - Schlomm, Thorsten

AU - Wilczak, Waldemar

PY - 2017/5/9

Y1 - 2017/5/9

N2 - FAM13C, a gene with unknown function is included in several mRNA signatures for prostate cancer aggressiveness. To understand the impact of FAM13C on prognosis and its relationship to molecularly defined subsets, we analyzed FAM13C expression by immunohistochemistry on a tissue microarray containing 12,400 prostate cancer specimens. Results were compared to phenotype, ERG status, genomic deletions of 3p, 5q, 6q and PTEN, and biochemical recurrence. FAM13C was detectable in cell nuclei of cancerous and non-neoplastic prostate cells. 67.5% of 9,633 interpretable cancers showed FAM13C expression: strong in 28.3%, moderate in 24.6% and weak in 14.6%. Strong FAM13C expression was linked to advanced pT stage, high Gleason grade, positive lymph node status, and early biochemical recurrence (p < 0.0001 each). FAM13C expression was associated with TMPRSS2:ERG fusions. It was present in 85% of ERG positive but in only 54% of ERG negative cancers (p < 0.0001), and in 91.1% of PTEN deleted but in only 69.2% of PTEN non-deleted cancers (p < 0.0001). The prognostic role of FAM13C expression was independent of classical and quantitative Gleason grade, pT stage, pN stage, surgical margin status and preoperative PSA. In conclusion, the results of our study demonstrate that expression of FAM13C is an independent prognostic marker in prostate cancer. Finding FAM13C also in non-neoplastic prostate tissues highlights the importance of properly selecting cancer-rich areas for RNA-based FAM13C expression analysis.

AB - FAM13C, a gene with unknown function is included in several mRNA signatures for prostate cancer aggressiveness. To understand the impact of FAM13C on prognosis and its relationship to molecularly defined subsets, we analyzed FAM13C expression by immunohistochemistry on a tissue microarray containing 12,400 prostate cancer specimens. Results were compared to phenotype, ERG status, genomic deletions of 3p, 5q, 6q and PTEN, and biochemical recurrence. FAM13C was detectable in cell nuclei of cancerous and non-neoplastic prostate cells. 67.5% of 9,633 interpretable cancers showed FAM13C expression: strong in 28.3%, moderate in 24.6% and weak in 14.6%. Strong FAM13C expression was linked to advanced pT stage, high Gleason grade, positive lymph node status, and early biochemical recurrence (p < 0.0001 each). FAM13C expression was associated with TMPRSS2:ERG fusions. It was present in 85% of ERG positive but in only 54% of ERG negative cancers (p < 0.0001), and in 91.1% of PTEN deleted but in only 69.2% of PTEN non-deleted cancers (p < 0.0001). The prognostic role of FAM13C expression was independent of classical and quantitative Gleason grade, pT stage, pN stage, surgical margin status and preoperative PSA. In conclusion, the results of our study demonstrate that expression of FAM13C is an independent prognostic marker in prostate cancer. Finding FAM13C also in non-neoplastic prostate tissues highlights the importance of properly selecting cancer-rich areas for RNA-based FAM13C expression analysis.

KW - Journal Article

U2 - 10.18632/oncotarget.16357

DO - 10.18632/oncotarget.16357

M3 - SCORING: Journal article

C2 - 28415558

VL - 8

SP - 31494

EP - 31508

JO - ONCOTARGET

JF - ONCOTARGET

SN - 1949-2553

IS - 19

ER -